The assumption that cancer is a disease confined to rogue cells and their immediate tissue environment is being systematically dismantled. Emerging evidence repositions the nervous system — both central and peripheral — as an active co-conspirator in tumor growth, survival, and resistance to therapy. For adults navigating cancer risk or treatment, this reframing has potentially far-reaching implications for how tumors are targeted and how stress and lifestyle factors biologically intersect with disease progression.
This review synthesizes a rapidly maturing body of research showing that tumors do not merely tolerate neural input — they actively exploit it. Gliomas, for instance, form genuine functional synapses with host neurons, co-opting both excitatory glutamatergic signaling (via AMPA and NMDA receptors) and inhibitory GABAergic pathways to sustain proliferation. Strikingly, analogous synaptic connections have now been documented in brain metastases and in small cell lung cancer, where both cortical and vagal neurons establish direct contacts with tumor cells. Beyond hardwired synaptic communication, tumors also respond to paracrine neurotransmitter gradients, autonomic innervation density, and whole-body neuroendocrine stress responses. These neural signals converge with established drug-resistance mechanisms — including p53-EGFR-ERK cascades, P-glycoprotein efflux pumps, ROS-redox programs, and adipokine-Hsp90 axes — collectively blunting the efficacy of chemotherapy, targeted agents, and immune checkpoint inhibitors.
This review is best classified as confirmatory-synthetic rather than paradigm-breaking in isolation: individual findings on neural-tumor crosstalk have been accumulating since the early 2010s, with landmark work on glioma synapses published in Nature around 2019-2021. The review's value lies in integrating previously siloed observations across tumor types and mechanistic pathways into a unified conceptual framework. Key limitations include the review's reliance on preclinical and early-phase data; translating synaptic disruption strategies into clinical tools remains nascent. Nevertheless, the convergence of stress physiology, autonomic tone, and drug resistance in a single mechanistic narrative raises genuinely actionable questions: whether beta-blockers, vagal nerve stimulation, or stress-reduction interventions could meaningfully modify treatment outcomes is now a scientifically credible — and actively investigated — hypothesis.